Finance Watch: Chinook Debuts With $65m For Precision Kidney Disease Medicines
Private Company Edition: The start-up intends to take multiple drug candidates into the clinic by 2021. Also, Graybug Vision raises an $80m series B and Finch closes a $53m series C.
You may also be interested in...
The financing, which brings the total raised by Juvenescence to $165m, comes as longevity R&D programs supported by the company move towards human testing.
Prompted by a presidential executive order on advancing kidney health, the US Medicare agency has proposed five new end-stage renal disease (ESRD) payment models to encourage greater use of home dialysis and kidney transplants to Medicare and Medicaid beneficiaries.
Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.